These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 37118849)

  • 1. Nanosome-Mediated Delivery Of Hdac Inhibitors and Oxygen Molecules for the Transcriptional Reactivation of Latent Hiv-Infected Cd4
    Hong J; Choi Y; Lee G; Kim J; Jang Y; Yoon CH; Seo HW; Park IK; Kang SH; Choi J
    Small; 2023 Sep; 19(37):e2301730. PubMed ID: 37118849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The histone deacetylase inhibitor vorinostat (SAHA) increases the susceptibility of uninfected CD4+ T cells to HIV by increasing the kinetics and efficiency of postentry viral events.
    Lucera MB; Tilton CA; Mao H; Dobrowolski C; Tabler CO; Haqqani AA; Karn J; Tilton JC
    J Virol; 2014 Sep; 88(18):10803-12. PubMed ID: 25008921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short Communication: The Broad-Spectrum Histone Deacetylase Inhibitors Vorinostat and Panobinostat Activate Latent HIV in CD4(+) T Cells In Part Through Phosphorylation of the T-Loop of the CDK9 Subunit of P-TEFb.
    Jamaluddin MS; Hu PW; Jan Y; Siwak EB; Rice AP
    AIDS Res Hum Retroviruses; 2016 Feb; 32(2):169-73. PubMed ID: 26727990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unique characteristics of histone deacetylase inhibitors in reactivation of latent HIV-1 in Bcl-2-transduced primary resting CD4+ T cells.
    Shan L; Xing S; Yang HC; Zhang H; Margolick JB; Siliciano RF
    J Antimicrob Chemother; 2014 Jan; 69(1):28-33. PubMed ID: 23999005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reactivation of latent HIV by histone deacetylase inhibitors.
    Shirakawa K; Chavez L; Hakre S; Calvanese V; Verdin E
    Trends Microbiol; 2013 Jun; 21(6):277-85. PubMed ID: 23517573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Class 1-Selective Histone Deacetylase (HDAC) Inhibitors Enhance HIV Latency Reversal while Preserving the Activity of HDAC Isoforms Necessary for Maximal HIV Gene Expression.
    Zaikos TD; Painter MM; Sebastian Kettinger NT; Terry VH; Collins KL
    J Virol; 2018 Mar; 92(6):. PubMed ID: 29298886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isoform-Selective Versus Nonselective Histone Deacetylase Inhibitors in HIV Latency Reversal.
    Boateng AT; Abaidoo-Myles A; Bonney EY; Kyei GB
    AIDS Res Hum Retroviruses; 2022 Aug; 38(8):615-621. PubMed ID: 35778852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular Gene Modulation of HIV-Infected CD4 T Cells in Response to Serial Treatment with the Histone Deacetylase Inhibitor Vorinostat.
    Maxwell JW; Falcinelli SD; Nefedov A; Dorfmeier C; Wu G; Dewey M; Webber AL; Archin NM; Margolis DM; Hazuda DJ; Barnard RJO; Howell BJ
    J Virol; 2020 Jun; 94(13):. PubMed ID: 32295913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A New Quinoline BRD4 Inhibitor Targets a Distinct Latent HIV-1 Reservoir for Reactivation from Other "Shock" Drugs.
    Abner E; Stoszko M; Zeng L; Chen HC; Izquierdo-Bouldstridge A; Konuma T; Zorita E; Fanunza E; Zhang Q; Mahmoudi T; Zhou MM; Filion GJ; Jordan A
    J Virol; 2018 May; 92(10):. PubMed ID: 29343578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors.
    Archin NM; Keedy KS; Espeseth A; Dang H; Hazuda DJ; Margolis DM
    AIDS; 2009 Sep; 23(14):1799-806. PubMed ID: 19590405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quiescence Promotes Latent HIV Infection and Resistance to Reactivation from Latency with Histone Deacetylase Inhibitors.
    Painter MM; Zaikos TD; Collins KL
    J Virol; 2017 Dec; 91(24):. PubMed ID: 29021396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing.
    Wei DG; Chiang V; Fyne E; Balakrishnan M; Barnes T; Graupe M; Hesselgesser J; Irrinki A; Murry JP; Stepan G; Stray KM; Tsai A; Yu H; Spindler J; Kearney M; Spina CA; McMahon D; Lalezari J; Sloan D; Mellors J; Geleziunas R; Cihlar T
    PLoS Pathog; 2014 Apr; 10(4):e1004071. PubMed ID: 24722454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat.
    Olesen R; Vigano S; Rasmussen TA; Søgaard OS; Ouyang Z; Buzon M; Bashirova A; Carrington M; Palmer S; Brinkmann CR; Yu XG; Østergaard L; Tolstrup M; Lichterfeld M
    J Virol; 2015 Oct; 89(20):10176-89. PubMed ID: 26223643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation.
    Rasmussen TA; Schmeltz Søgaard O; Brinkmann C; Wightman F; Lewin SR; Melchjorsen J; Dinarello C; Østergaard L; Tolstrup M
    Hum Vaccin Immunother; 2013 May; 9(5):993-1001. PubMed ID: 23370291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy for latent HIV-1 infection: the role of histone deacetylase inhibitors.
    Manson McManamy ME; Hakre S; Verdin EM; Margolis DM
    Antivir Chem Chemother; 2014 Jan; 23(4):145-9. PubMed ID: 24318952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone deacetylase inhibitor chidamide promotes reactivation of latent human immunodeficiency virus by introducing histone acetylation.
    Kuai Q; Lu X; Qiao Z; Wang R; Wang Y; Ye S; He M; Wang Y; Zhang T; Wu H; Ren S; Yu Q
    J Med Virol; 2018 Sep; 90(9):1478-1485. PubMed ID: 29704439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genome-wide CRISPR screens identify combinations of candidate latency reversing agents for targeting the latent HIV-1 reservoir.
    Dai W; Wu F; McMyn N; Song B; Walker-Sperling VE; Varriale J; Zhang H; Barouch DH; Siliciano JD; Li W; Siliciano RF
    Sci Transl Med; 2022 Oct; 14(667):eabh3351. PubMed ID: 36260688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The histone deacetylase inhibitor ITF2357 decreases surface CXCR4 and CCR5 expression on CD4(+) T-cells and monocytes and is superior to valproic acid for latent HIV-1 expression in vitro.
    Matalon S; Palmer BE; Nold MF; Furlan A; Kassu A; Fossati G; Mascagni P; Dinarello CA
    J Acquir Immune Defic Syndr; 2010 May; 54(1):1-9. PubMed ID: 20300007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective HDAC inhibition for the disruption of latent HIV-1 infection.
    Barton KM; Archin NM; Keedy KS; Espeseth AS; Zhang YL; Gale J; Wagner FF; Holson EB; Margolis DM
    PLoS One; 2014; 9(8):e102684. PubMed ID: 25136952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and evaluation of DAG-lactone derivatives with HIV-1 latency reversing activity.
    Ishii T; Kobayakawa T; Matsuda K; Tsuji K; Ohashi N; Nakahata S; Noborio A; Yoshimura K; Mitsuya H; Maeda K; Tamamura H
    Eur J Med Chem; 2023 Aug; 256():115449. PubMed ID: 37224601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.